These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 21087350)
1. Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer. Kawakami K; Matsunoki A; Kaneko M; Saito K; Watanabe G; Minamoto T Cancer Sci; 2011 Jan; 102(1):166-74. PubMed ID: 21087350 [TBL] [Abstract][Full Text] [Related]
2. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Van Rijnsoever M; Elsaleh H; Joseph D; McCaul K; Iacopetta B Clin Cancer Res; 2003 Aug; 9(8):2898-903. PubMed ID: 12912934 [TBL] [Abstract][Full Text] [Related]
3. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer. Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637 [TBL] [Abstract][Full Text] [Related]
4. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker. Nishio M; Sakakura C; Nagata T; Komiyama S; Miyashita A; Hamada T; Kuryu Y; Ikoma H; Kubota T; Kimura A; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Ida H; Ito K; Chiba T; Ito Y; Otsuji E Anticancer Res; 2010 Jul; 30(7):2673-82. PubMed ID: 20682997 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy. Yamada H; Iinuma H; Watanabe T Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408 [TBL] [Abstract][Full Text] [Related]
6. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer. Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677 [TBL] [Abstract][Full Text] [Related]
7. Association of the CpG island methylator phenotype with family history of cancer in patients with colorectal cancer. Frazier ML; Xi L; Zong J; Viscofsky N; Rashid A; Wu EF; Lynch PM; Amos CI; Issa JP Cancer Res; 2003 Aug; 63(16):4805-8. PubMed ID: 12941799 [TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer. Kaneko M; Kotake M; Bando H; Yamada T; Takemura H; Minamoto T BMC Cancer; 2016 Dec; 16(1):945. PubMed ID: 27955637 [TBL] [Abstract][Full Text] [Related]
9. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Elsaleh H; Powell B; McCaul K; Grieu F; Grant R; Joseph D; Iacopetta B Clin Cancer Res; 2001 May; 7(5):1343-9. PubMed ID: 11350904 [TBL] [Abstract][Full Text] [Related]
10. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Jover R; Nguyen TP; Pérez-Carbonell L; Zapater P; Payá A; Alenda C; Rojas E; Cubiella J; Balaguer F; Morillas JD; Clofent J; Bujanda L; Reñé JM; Bessa X; Xicola RM; Nicolás-Pérez D; Castells A; Andreu M; Llor X; Boland CR; Goel A Gastroenterology; 2011 Apr; 140(4):1174-81. PubMed ID: 21185836 [TBL] [Abstract][Full Text] [Related]
11. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Ogino S; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS Int J Cancer; 2008 Jun; 122(12):2767-73. PubMed ID: 18366060 [TBL] [Abstract][Full Text] [Related]
12. BRAF mutation is associated with the CpG island methylator phenotype in colorectal cancer from young patients. Ang PW; Li WQ; Soong R; Iacopetta B Cancer Lett; 2009 Jan; 273(2):221-4. PubMed ID: 18778891 [TBL] [Abstract][Full Text] [Related]
13. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Ogino S; Meyerhardt JA; Kawasaki T; Clark JW; Ryan DP; Kulke MH; Enzinger PC; Wolpin BM; Loda M; Fuchs CS Virchows Arch; 2007 May; 450(5):529-37. PubMed ID: 17372756 [TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Elsaleh H; Iacopetta B Clin Colorectal Cancer; 2001 Aug; 1(2):104-9. PubMed ID: 12445368 [TBL] [Abstract][Full Text] [Related]
15. Three DNA methylation epigenotypes in human colorectal cancer. Yagi K; Akagi K; Hayashi H; Nagae G; Tsuji S; Isagawa T; Midorikawa Y; Nishimura Y; Sakamoto H; Seto Y; Aburatani H; Kaneda A Clin Cancer Res; 2010 Jan; 16(1):21-33. PubMed ID: 20028768 [TBL] [Abstract][Full Text] [Related]
16. Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes. Kaneda A; Yagi K Cancer Sci; 2011 Jan; 102(1):18-24. PubMed ID: 21159060 [TBL] [Abstract][Full Text] [Related]
17. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C; Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036 [TBL] [Abstract][Full Text] [Related]
18. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812 [TBL] [Abstract][Full Text] [Related]
19. CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer. Jo P; Jung K; Grade M; Conradi LC; Wolff HA; Kitz J; Becker H; Rüschoff J; Hartmann A; Beissbarth T; Müller-Dornieden A; Ghadimi M; Schneider-Stock R; Gaedcke J Surgery; 2012 Apr; 151(4):564-70. PubMed ID: 22001634 [TBL] [Abstract][Full Text] [Related]
20. Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle. Tejpar S; Saridaki Z; Delorenzi M; Bosman F; Roth AD J Natl Cancer Inst; 2011 Jun; 103(11):841-4. PubMed ID: 21597023 [No Abstract] [Full Text] [Related] [Next] [New Search]